U.S. markets open in 7 hours 26 minutes

Sensei Biotherapeutics, Inc. (SNSE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.16-0.67 (-6.19%)
At close: 4:00PM EDT

Sensei Biotherapeutics, Inc.

1405 Research Boulevard
Suite 125
Rockville, MD 20850
United States
240 243 8000
http://www.senseibio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Mr. John K. CelebiPres, CEO & Director532.63kN/A1972
Dr. Robert Hamilton PierceChief Scientific Officer488.03kN/A1964
Ms. Anupama Hoey M.B.A., M.S.Chief Bus. Officer121.65kN/A1971
Ms. Erin ColganSr. VP of Fin. & Admin.N/AN/A1981
Dr. Steven A. FullerChief Biopharmaceuticals Devel. OfficerN/AN/AN/A
Ms. Lora PikeVP of Investor Relations & CommunicationsN/AN/AN/A
Dr. Marie-Louise Fjallskog M.D., Ph.D.Chief Medical OfficerN/AN/A1964
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.

Corporate Governance

Sensei Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.